Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Anthracyclines, such as daunorubicin (DNR), rubidazone (RBD) and adriamycin (ADR) are intercalating drugs used in cancer chemotherapy. They inhibit synthesis of DNA and RNA, break DNA and inhibit mitochondrial oxidative chain. Their antitumoral experimental activities depend upon type of drug, tumor and route of administration. After i.v. administration, the drug is present in all tissues except central nervous system. Its disappearance from the plasma is biphasic with a long terminal half life, justifying intermittent chemotherapy. Anthracyclines metabolism occurs mainly in liver micrososomes, and 90% metabolites are excreted in the bile. The main toxicity is cardiac, as a congestive heart failure which appears when a cumulated drug dose is overcome. In man only, a few derivatives have been studied, compounds with activity and no cardiotoxicity are still in research. Action of malignancies depends on type of derivative. We use DNR since 1967, it is a remarkable active drug in induction treatment of AML, it is the only active drug on acute promyelocytic leukemia, and it increases number of remissions in all of adult patients and severe forms of children ALL. Adriamycin (ADR) is active on solid tumors (osteosarcoma, breast and thyroid cancers) and lymphomas. With rubidazone (RBD) we obtain 2/3 of remissions in acute monoblastic leukemia, and it is easier to use than DNR and equally active on AML. RBD is also active on severe cases of lymphomas (lymphosarcomas and Hodgkin's disease). A new compound DEA 14 DNR seems interesting: experimental antitumor activity is high (compared to DNR, RBD and ADR) and it appears to possess activity on solid tumors in man.
 ...
PMID:[Survey of anthracyclines derivatives in haematology (author's transl)]. 67 74

The cellular change (phenotypic) leading to leukemia may involve a disorder of leukocyte maturation, but the etiologic molecular change (genotypic) remains unknown. We present evidence here that human leukemic cells contain type-C viral information and consider the possible significance of this observation in the context of a working hypothesis. We reexamine reticuloendothelial neoplasms in the light of newer immunologic, cytochemical, and ultrastructural methods for identifying cells of the T-lymphocytic, B-lymphocytic, and monocyte-macrophage systems. Use of these methods has led to a challenging concept of malignant lymphomas as neoplasms of various anatomic and functional compartments of the immune system. Functional studies, although still in their inception, have already provided provocative clues in the etiology and pathophysiology of these disorders. Advances in laboratory research have been paralled by dramatic changes in clinical oncology, as evidenced by trends in the treatment of acute lymphocytic leukemia, acute myelogenous leukemia, Hodgkin's disease, and diffuse histocyte lymphoma.
 ...
PMID:Current concepts of leukemia and lymphoma: etiology, pathogenesis, and therapy. 78 94

Leucocytes from normal donors and leukemia patients were isolated and lebelled in vitro with 32P-orthophosphate in order to compare labelling characteristics of nuclear high-molecular weight RNA, labelling characteristics, nucleotide compositions and oligonucleotide frequencies of ribosomal 28 S RNA. These studies revealed 1. structural microheterogeneity of 28 S RNA between the various leukemia cells studies without presenting a leukemia-specific structural marker, 2. an impaired production of ribosomal 28 S RNA from its nuclear precursor 45 S RNA in acute myeloblastic leukemia compared to PHA-stimulated normal lymphocytes. In the second part of this work, the influence of RNA from immunocompetent lymphocytes on the PHA-stimulation of M. Hodgkin lymphocytes was analyzed; the third part deals with studies on macromolecular carriers forcytostatic anthracyclines in human leukemia cells.
 ...
PMID:[Macromolecular biochemistry of normal and pathological white blood cells in man]. 83 49

Two cases of acute myeloblastic leukemia were observed in Hodgkin's disease patients two and five years following intensive radiation therapy. Sixteen additional cases of acute granulocytic leukemia occurring in radiation-treated Hodgkin's disease patients have been reported in the literature and are reviewed. It is suggested that the development of acute leukemia was related to irradiation in these patients, and that additional such cases could be expected with the use of intensive radiation and chemotherapy, a risk probably justified in view of the improved control of Hodgkin's disease achieved by these programs.
 ...
PMID:Acute granulocytic leukemia in Hodgkin's disease. 105 2

Chromosome analyses using the Giemsa banding technique were performed on bone marrow cells in a patient with the association of Hodgkin's disease and acute myeloid leukaemia. All cells had an abnormal karyotype showing an extra chromosome No. 14, loss of one chromosome No. 17 and gain of one chromosome No. 18. These abnormalities are in many respects similar to the karyotype changes of lymphoid cells in malignant lymphomas, suggesting a pathogenetic relationship between the two disorders.
 ...
PMID:Chromosome abnormalities identified by banding technique in a patient with acute myeloid leukaemia complicating Hodgkin's disease. 105 40

The NBT reduction test and determination of alkaline phosphatase activity in the peripheral blood granulocytes (FAG) were done in 94 subjects including 30 blood donors donating blood for the first time and 64 cases of various haematological syndromes. Raised proportion of formazan granulocytes was found in patients with pancytopenia, acute myeloid leukaemia, chronic myeloid leukaemia during blastic exacerbation, Hodgkin's disease during exacerbation and lymphosarcoma. These results correlated with increased FAG activity. Lower proportions of formazan granulocytes capable of spontaneous reduction of NBT were found in patients with chronic myeloid leukaemia, in immunohaemolytic anaemias and in plasmocytoma. Of all the above syndromes only in chronic myeloid leukaemia impaired ability of formazan cell formation parallelled decreased FAG activity. In the remaining syndromes FAG activity in the granulocytes was normal or raised. In the remissions of Hodgkin's disease a fall was observed in the proportion of formazan granulocytes to values of FAG. In chronic myeloid leukaemia the proportion of formazan cells showed considerable fluctuations and no correlation was observed between the proportion of formazan cells and FAG activity.
 ...
PMID:[Spontaneous nitroblue terazolium reduction test (NBT) by peripheral blood granulocytes in healthy subjects and in some hematologic syndromes]. 105 43

Two cases of the development of acute myeloid leukemia (AML) after treatment with alkylating agents are reported. In Case 1, melphalan and then cyclophosphamide had been given for multiple myeloma. 46 months after onset of cytostatic treatment AML occurred, as confirmed cytochemically and by qualitative determination of urinary lysozyme. In Case 2, cyclophosphamide had been given for rheumatoid arthritis. After a latency of 34 months 'smouldering leukaemia' developed with an atypical monocytic leukaemic cell population. In a third case, multiple myeloma and monocytic leukaemia developed synchronously. The causative role of melphalan and cyclophosphamide in the development of AML seems securely established. Despite the risk of alkylating agents in the treatment of multiple myeloma or Hodgkin's disease causing AML, they should not be replaced, as other drugs have been shown to be less beneficial. On the other hand, alkylating agents should be used with great caution in the treatment of non-malignant diseases.
 ...
PMID:[Plasmocytoma, alkylating agents, and acute myeloid leukemia (author's transl)]. 105 6

Rubidazone was used as sole chemotherapy in 170 adults and children with acute leukemia and sarcoma. When rubidazone was employed to treat the first attack, complete remission was achieved in : 1) 40 out of 70 patients (57%) with AML; 2) two out of six patients with AML where previous chemotherapy had failed; 3) four out of five patients with ALL; 4) 12 out of 14 patients with acute monoblastic leukemia. When used to treat relapse, rubidazone produced complete remission in : 1) 14 out of 31 cases of AML; 2) 18 out of 39 cases of ALL; 3) 2 out of 3 cases of non-Hodgkin lymphoma. Treatment of a case of rhabdomyosarcoma was unsuccessful. In the treatment of acute myeloblastic and monoblastic leukemias, it may be concluded that rubidazone induces a higher rate of complete remission than any other previously reported drug which was used alone. It also achieves remission rates similar to those resulting from a combination of daunorubicin and Ara-C. Furthermore, when compared with daunorubicin, rubidazone allows better control of the induction of aplasia.
 ...
PMID:Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemias and other malignancies. 106 26

Among a family of four persons, three members each had a separate malignant disease during a 3-year period. The mother and father concurrently had multiple myeloma and Hodgkin's disease, respectively, and less than 3 years later, their only son was found to have acute granulocytic leukemia. No increased incidence of deaths attributed to Hodgkin's disease, acute leukemia, or multiple myeloma was found in the community. No other cause for this cluster of hematologic malignancies could be found.
 ...
PMID:Multiple myeloma, acute leukemia, and Hodgkin's disease. Occurrence in three of four family members. 106 53

The simultaneous occurrence of nodular poorly differentiated lymphocytic lymphoma (NLPD) and acute myelomonocytic leukemia (AMML) was confirmed by the histologic examination of lymph node section, peripheral blood, and bone marrow. This association in the absence of previous chemotherapy or radiotherapy has not been previously documented. There have been six previous case reports of patients with non-Hodgkin's lymphocytic lymphoma who, during treatment with alkylating agents or radiotherapy, developed acute myeloid leukemia (AML). These methods of therapy may have had a leukemogenic role in such patients. The possible relationship between these two diseases is discussed.
 ...
PMID:Simultaneous occurrence of non-Hodgkin's lymphoma and acute myelomonocytic leukemia. 106 5


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>